

10-07-02

62/1645

RECEIVED
OCT 08 2002
TECH CENTER 160012000

PTO/SB/1008-00

Approved for use through 10/31/02. OMB 0001-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/086,973	
	Filing Date	March 1, 2002	
	First Named Inventor	Kesavan ESUVARANATHAN	
	Group Art Unit	1645	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	25 + 108 REFERENCES	Attorney Docket No.	488002000200

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form PTO-1449 + 2 copies (21 Pages) 108 References Return Receipt Postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement (3 Pages)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
Signature	
Date	October 3, 2002

CERTIFICATE OF MAILING BY "EXPRESS MAIL"	
Express Mail Label No.: EV093219533US	Date of Deposit: October 3, 2002
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
 Tamara Alcaraz	

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT
Docket No. 488002000200

TECH CENTER 1600/2900

RECEIVED
OCT 08 2002

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV093219533US

Date of Deposit: October 3, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

[Signature]
Tamara Alcaraz

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Kesavan ESUVARANATHAN, et al.

Serial No.: 10/086,973

Filing Date: March 1, 2002

For: METHODS AND COMPOSITIONS FOR
DELIVERY OF PHARMACEUTICAL
AGENTS

Examiner: To Be Assigned

Group Art Unit: 1645

#3 / I.D.S.

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.



This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.



In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 488002000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: October 3, 2002

Respectfully submitted,

By: 

Madeline I. Johnston
Registration No. 36,174

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5840
Facsimile: (650) 494-0792



CH CENTER 1609/2900

OCT 08 2002

RECEIVED

#3/I.D.S.

PTO/SB/08 (2-92)

Sheet 1 of 7

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 488002000200

Application Number 10/086,973

Applicant

Kesavan ESUVARANATHAN, et al.

Filing Date March 1, 2002

Group Art Unit 1645

Mailing Date: October 3, 2002

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	11/23/1993	5,264,618	Felgner et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	2.	10/27/1994	CA 2,161,225	Canada			
	3.	12/28/1995	CA 2,193,502	Canada			
	4.	03/21/1996	CA 2,199,004	Canada			
	5.	02/26/1998	CA 2,263,705	Canada			
	6.	04/01/1999	CA 2,303,884	Canada			
	7.	10/27/1994	WO 94/23697 A1	WIPO			
	8.	03/21/1996	WO 96/08235 A1	WIPO			
	9.	11/28/1996	WO 96/37194 A1	WIPO			
	10.	12/19/1996	WO 96/40962 A1	WIPO			
	11.	12/19/1996	WO 96/40963 A1	WIPO			
	12.	02/26/1998	WO 98/07408 A1	WIPO			
	13.	04/02/1998	WO 98/13026 A1	WIPO			
	14.	09/17/1998	WO 40499 A1	WIPO			
	15.	10/15/1998	WO 98/44909 A1	WIPO			
	16.	11/19/1998	WO 98/51285 A2	WIPO			
	17.	04/01/1999	WO 99/15206 A1	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	18.	A Conference Supplement to Cancer Gene Therapy. (November/December 1999) Gene Therapy of Cancer VIII. San Diego, California December 9-11, 1999. 6(6):total pages 2.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

OCT 08 2002

PTO/SB/08 (2-92)

Sheet 2 of 7

Form PTO-1449

TECH CENTER 1600/2000

Docket Number 488002000200

Application Number 10/086,973

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)


Applicant

Kesavan ESUVARANATHAN, et al.

Filing Date March 1, 2002

Group Art Unit 1645

Mailing Date: October 3, 2002



- | | |
|--------|---|
| 19. | Abe, K. et al. (December 1995). "Enhanced Nasal Delivery of Luteinizing Hormone Releasing Hormone Agonist Buserelin by Oleic Acid Solubilized and Stabilized in Hydroxypropyl-Beta-Cyclodextrin." |
| 20. | Abdou, S. et al. (1997). "Beta-Cyclodextrin Derivatives as Carriers to Enhance the Antiviral Activity of an Antisense Oligonucleotide Directed Toward a Coronavirus Intergenic Consensus Sequence," <i>Arch. Virol.</i> 142(8):1585-1602. |
| 21. | Alton, E.W.F.W. et al. (October 1993). "Non-Invasive Liposome-Mediated Gene Delivery Can Correct the Ion Transport Defect in Cystic Fibrosis Mutant Mice," <i>Natl. Genet.</i> 5:135-142. |
| 22. | Belldegrin, A. S. et al. (June 1998). "Superficial Bladder Cancer: The Role of Interferon- α ," <i>The J. of Urology</i> 159:1793-1801. |
| ** 23. | Becket, G. et al. (March 1999). "Improvement of the In Vitro Dissolution of Praziquantel by Complexion with Alpha-, Beta- and Gamma-Cyclodextrins," <i>Int. J. Pharm.</i> 79(1):65-71. |
| ** 24. | Bibby, D.C, et al. (March 2000). "Mechanisms by which Cyclodextrins Modify Drug Release from Polymeric Drug Delivery," <i>Int. J. Pharm.</i> 197(1-2):1-11. |
| 25. | Brigham, K. L. MD et al. (October 1989). "Rapid Communication: <i>In Vivo</i> Transfection of Murine Lungs with a Functioning Prokaryotic Gene Using a Liposome Vehicle," <i>Am. J. Med. Sci.</i> 298(4):278-281 |
| 26. | Brosman, S. A. (August 1992). "Bacillus Calmette-Guérin Immunotherapy," <i>Urol. Clin. of North Am.</i> 19(3):557-564. |
| ** 27. | Chang, s. L. and Banga, a. K. (June 1998). "Transdermal Iontophoretic Delivery of Hydrocortisone from Cyclodextrin Solutions," <i>J. Pharm. Pharmacol.</i> 50(6):635-640. |
| 28. | Bui, L. A. (December 1997). " <i>In Vivo</i> Therapy of Hepatocellular Carcinoma with a Tumor-Specific Adenoviral Vector Expressing Interleukin-2," <i>Hum. Gene Ther.</i> 8:2173-2182. |
| 29. | Chen, L. (1997). "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and its Inhibition by the IL-12 p40 Subunit Homodimer," <i>J. Immunology</i> 159:351-359. |
| 30. | Chow, N-H. et al. (1998). "Potential Value of Urinary Intercellular Adhesion Molecule-1 Determination in Patients with Bladder Cancer," <i>Adult Urol.</i> 52(6):1015-1019. |
| 31. | Colombo, M. P. and Forni, G. (February 1994). "Cytokine Gene Transfer in Tumor Inhibition and Tumor Therapy: Where Are We Now?" <i>Imm. Today</i> 15(2):48-51. |
| 32. | Crook, K. et al. (1998). "Inclusion of Cholesterol in DOTAP Transfection Complexes Increases the Delivery of DNA to Cells In Vitro in the Presence of Serum," <i>Gene Ther.</i> 5:137-143. |
| 33. | Cross, A. H. et al. (2000). "A Catalyst of Peroxynitrite Decomposition Inhibits Murine Experimental Autoimmune Encephalomyelitis," <i>J. of Neurol.</i> 107:21-28. |
| 34. | Croyle, M. A. et al. (1998). "Beta Cyclodextrins Enhance Adenoviral-Mediated Gene Delivery to the Intestine," <i>Pharm. Res.</i> 15(9):1348-1355. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

OCT 08 2002

PTO/SB/08 (2-92)

Sheet 3 of 7

Form PTO-1449

TECH CENTER 1600/2300

Docket Number 488002000200

Application Number 10/086,973

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Kesavan ESUVARANATHAN, et al.

Filing Date March 1, 2002

Group Art Unit 1645

Mailing Date: October 3, 2002



- | | |
|-----|---|
| 35. | Debs, R. J. et al. (June 1990). "Regulation of Gene Expression <i>In Vivo</i> by Liposome-mediated Delivery of a Purified Transcription Factor," <i>J. Biol. Chem.</i> 265(18):10189-10192. |
| 36. | Eastman, S. J. et al. (April 1997). "A Concentrated and Stable Aerosol Formulation of Cationic Lipid: DNA Complexes Giving High-level Gene Expression in Mouse Lung," <i>Hum. Gene. Ther.</i> 8(6):765-773. |
| 37. | Felgner, P. L. et al. (November 1987). "Lipofection: A Highly Efficient, Lipid-mediated DNA-transfection Procedure," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84:7413-7416. |
| 38. | Felgner, J. H. et al. (January 1994). "Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations," <i>J. Biol. Chem.</i> 269(4):2550-2561. |
| 39. | Freeman, D. J. and Niven, R. W. (1996). "The Influence of Sodium Glycocholate and other Additives on the <i>In Vivo</i> Transfection of Plasmid DNA in the Lungs," <i>Pharm. Res.</i> 13(2):202-209. |
| 40. | Gabrilovich, D. I. et al. (1996). "Dendritic Cells in Antitumor Immune Responses. I. Defective Antigen Presentation in Tumor-Bearing Hosts," <i>Cell. Imm.</i> 170(0139):101-110. |
| 41. | Gan, Y. H. et al. (1999). "Antitumour Immunity of Bacillus Calmette-Guerin and Interferon Alpha in Murine Bladder Cancer," <i>Eur. J. Cancer</i> 35(7):1123-1129. |
| 42. | Gao, X. and Huang, L. (January 1996). "Potentiation of Cationic Liposome-Mediated Gene Delivery by Polycations," <i>Biochem.</i> 35(3):1027-1036. |
| 43. | Gimpl, G. et al. (1997). "Cholesterol as Modulator of Receptor Function," <i>Biochem.</i> 36(36):10959-10974. |
| 44. | Goeddel, D. V. ed. (1990). <i>Methods in Enzymology: Gene Expression Technology</i> . Academic Press Inc., San Diego, Calif. (Table of Contents). 185:v-ix. |
| 45. | Golumbek, P. T. et al. (November 1991). "Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interlukin-4," <i>Science</i> 254(5032):713-716. |
| 46. | Gonzalez, H. et al. (1999). "New Class of Polymers for the Delivery of Macromolecular Therapeutics," <i>Bioconj. Chem.</i> 10:1068-1074. |
| 47. | Grosse, P. Y. et al. (1998). "Antiproliferative Effect of Methyl- β -Cyclodextrin <i>In Vitro</i> and in Human Tumour Xenografted Athymic Nude Mice," <i>Br. J. of Can.</i> 78(9):1165-1169. |
| 48. | Harimoto, K. et al. (1998). " <i>In Vivo</i> Gene Transfer Methods in the Bladder Without Viral Vectors," <i>Br. J. of Urol.</i> 81:870-874. |
| ** | 49. Hirayama, F. and Uekama, K. (March 1999). "Cyclodextrin-Based Controlled Drug Release System," <i>Adv. Drug Deliv. Rev.</i> 36(1):125-141. |
| 50. | Hofland, H. E. (July 1996). "Formation of Stable Cationic Lipid/DNA Complexes for Gene Transfer," <i>Proc. Nat. Acad. Sci. U.S.A.</i> 93(14):7305-7309. |
| 51. | Hovgaard, L. and Brondsted, H. (1995). "Drug Delivery Studies in Caco-2 Monolayers. IV. Absorption Enhancer Effects of Cyclodextrins," <i>Pharm. Res.</i> 12(9):1328-1332. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 488002000200

Application Number 10/086,973

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)


Applicant

Kesavan ESUVARANATHAN, et al.

Filing Date March 1, 2002

Group Art Unit 1645

Mailing Date: October 3, 2002



- | | |
|--------|---|
| 52. | Hui, S. W. et al. (August 1996). "The Role of Helper Lipids in Cationic Liposome-mediated Gene Transfer," <i>Biophys J.</i> 71:590-599. |
| 53. | Hyde, S. C. et al. (March 1993). "Correction of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy," <i>Nature</i> 362(6417):250-255. |
| 54. | Jackson, A. M. et al. (1995). "Changes in Urinary Cytokines and Soluble Intercellular Adhesion Molecule-1 (ICAM-1) in Bladder Cancer Patients After Bacillus Calmette-Guérin (BCG) Immunotherapy," <i>Clin. Exp. Immunol.</i> 99:369-375. |
| 55. | Kaufman, R. J. et al. (January 1987). "Translational Efficiency of Polycistronic mRNAs and Their Utilization to Express Heterologous Genes in Mammalian Cells," <i>EMBO J.</i> 6:187-193. |
| 56. | Kurusu, H. et al. (1994). "Cytokine-mediated Antitumor Effect of Bacillus Calmette-Guérin on Tumor Cells In Vitro," <i>Cancer Immunol. Immunother.</i> 39:249-253. |
| 57. | Lamm, D. L., MD (August 1992). "Complications of Bacillus Calmette-Guérin Immunotherapy," <i>Urol. Clin. North Am.</i> 19(3):565-572. |
| 58. | Lasic, D. D. and Templeton, N. S. (1996). "Liposomes in Gene Therapy," <i>Adv. Drug Deliv. Rev.</i> 20:221-266. |
| 59. | Lee, E. R. et al. (September 1996). "Detailed Analysis of Structures and Formulations of Cationic Lipids for Efficient Gene Transfer to the Lung," <i>Hum. Gene Ther.</i> 7(14):1701-1717. |
| 60. | Lee, S. S. et al. (July 1994). "Intravesical Gene Therapy: <i>In Vivo</i> Gene Transfer Using Recombinant Vaccinia Virus Vectors," <i>Cancer Res.</i> 54:3325-3328. |
| 61. | Li, Y. et al. (January 1999). "Loss of Adenoviral Receptor Expression in Human Bladder Cancer Cells: A Potential Impact on the Efficacy of Gene Therapy," <i>Cancer Res.</i> 59:325-330. |
| 62. | Liu, F. et al. (December 1996). "New Cationic Lipid Formulations for Gene Transfer," <i>Pharma. Res.</i> 13(12):1856-1860. |
| 63. | Liu, F. et al. (1996). "Effect of Non-Ionic Surfactants on the Formation of DNA/Emulsion Complexes and Emulsion-Mediated Gene Transfer," <i>Pharm. Res.</i> 13(11):1642-1646. |
| ** 64. | Lopez, R. F. et al. (April 2000). "Influence of Cyclodextrin Complexation on the In Vitro Permeation and Skin Metabolism of Dexamethasone," <i>Int. J. Pharm.</i> 200(1):127-132. |
| 65. | Loftsson, T. (1998). "Increasing the Cyclodextrin Complexation of Drugs and Drug Bioavailability Through Addition of Water-Soluble Polymers," <i>Pharmazie</i> 53(11):733-740. |
| 66. | Malone, R. W. et al. (August 1989). "Cationic Liposome-mediated RNA Transfection," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 86:6077-6081. |
| 67. | Milelia, M. (1999). "Interleukin-2 Gene Transfer Into Human Transitional Cell Carcinoma of the Urinary Bladder," <i>Brit. J. of Can.</i> 79(5/6):770-779. |
| 68. | Mizoguchi, H. et al. (December 1992). "Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice," <i>Science</i> 258:1795-1798. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

OCT 08 2002

PTO/SB/08 (2-92)

Sheet 5 of 7

Form PTO-1449

TECH CENTER 1600/2000

Docket Number 488002000200

Application Number 10/086,973

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Kesavan ESUVARANATHAN, et al.

Filing Date March 1, 2002

Group Art Unit 1645

Mailing Date: October 3, 2002



- | | |
|-----|--|
| 69. | Morales, A. et al. (August 1976). "Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors," <i>J. Urol.</i> 116:180-183. |
| 70. | Morris, B. D. et al. (August 1994). "Adenoviral-mediated Gene Transfer to Bladder In Vivo," <i>J. Urol.</i> 152:506-509. |
| 71. | Nabel, G. J. et al. (December 1993). "Direct Gene Transfer with DNA-liposome Complexes in Melanoma: Expression, Biologic Activity, and Lack of Toxicity in Humans," <i>Proc. Natl. Acad. Sci. U S A</i> 90:11307-11311. |
| 72. | Nabel, E. G. et al. (September 1990). "Site-specific Gene Expression In Vivo by Direct Gene Transfer into the Arterial Wall," <i>Science</i> 249(4974):1285-1288. |
| 73. | Nabel, E. G. et al. (June 1992). "Transduction of a Foreign Histocompatibility Gene into the Arterial Wall Induces Vasculitis," <i>Proc. Nat. Acad. Sci. U S A</i> 89(11):5157-5161. |
| 74. | Nseyo, U. O. and Lamm, D. L. (October 1996). "Therapy of Superficial Bladder Cancer," <i>Semi. in Oncol.</i> 23(5):598-604. |
| 75. | Otsuji, M. et al. (November 1996). "Oxidative Stress by Tumor-deprived Macrophages Suppresses the Expression of CD3 ζ Chain of T-Cell Receptor Complex and Antigen-specific T-Cell Responses," <i>Proc. Natl. Acad. Sci. U S A</i> 93:13119-13124. |
| 76. | Pang, L. et al. (1999). "Membrane Cholesterol Modulates Galanin-GalR2 Interaction," <i>Biochem.</i> 38(37):12003-12011. |
| 77. | Patard, J. J. et al. (1998). "Immune Response Following Intravesical Bacillus Calmette-Guerin Instillations in Superficial Bladder Cancer: A Review," <i>Urol. Res.</i> 26:155-159. |
| 78. | Plautz, G. E. et al. (May 1993). "Immunotherapy of Malignancy by In Vivo Gene Transfer into Tumors," <i>Proc. Nat. Acad. Sci. U S A</i> 90:4645-4649. |
| 79. | Rajewski, R. A. and Stella, V. J. (November 1996). "Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery," <i>J. Pharm. Sci.</i> 85(11):1142-1169. |
| 80. | Rodal, S. K. et al. (April 1999). "Extraction of Cholesterol with Methyl- β -Cyclodextrin Perturbs Formation of Clathrin-coated Endocytic Vesicles," <i>Mol. Biol. Cell</i> 10:961-974. |
| 81. | Ruponen, M. et al. (1999). "Interactions of Polymeric and Liposomal Gene Delivery Systems with Extracellular Glycosaminoglycans: Physicochemical and Transfection Studies," <i>Biochem. et Biophys. Acta</i> 1415:331-341. |
| 82. | Saito, S. et al. (July 1994). "Immunotherapy of Bladder Cancer with Cytokine Gene-modified Tumor Vaccines," <i>Can. Res.</i> 54:3516-3520. |
| 83. | Salazar-Onfray, F. (1997). "Down-Regulation of the Expression and Function of the Transporter Associated with Antigen Processing in Murine Tumor Cell Lines Expressing IL-10," <i>J. Immun.</i> 159:3195-3202. |
| 84. | Sander, B. et al. (August 1996). "Localization of IL-1, IL-2, IL-4, IL-8 and TNF in Superficial Bladder Tumors Treated with Intravesical Bacillus Calmette-Guerin," <i>J. Urol.</i> 156:536-541. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 488002000200

Application Number 10/086,973

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)


Applicant

Kesavan ESUVARANATHAN, et al.

Filing Date March 1, 2002

Group Art Unit 1645

Mailing Date: October 3, 2002



- | | |
|--------|---|
| 85. | Schmidt-Wolf, G. D. and Schmidt-Wolf, I. G. H. (April 1995). "Cytokines and Gene Therapy," <i>Immunology Today</i> 16(4):173-175. |
| 86. | Seed, B. (October 1987). "An LFA-3 cDNA Encodes a Phospholipid-linked Membrane Protein Homologous to its Receptor CD2," <i>Nature</i> 329:840-842. |
| 87. | Semple, S. C. et al. (1996). "Influence of Cholesterol on the Association of Plasma Proteins with Liposomes," <i>Biochem.</i> 35(8):2521-2525. |
| 88. | Song, Y. K. et al. (1997). "Characterization of Cationic Liposome-Mediated Gene Transfer In Vivo by Intravenous Administration," <i>Hum. Gene Ther.</i> 8(13):1585-1594. |
| 89. | Stephan, D. J. et al. (October 1996). "A New Cationic Liposome DNA Complex Enhances the Efficiency of Arterial Gene Transfer In Vivo," <i>Hum. Gene Ther.</i> 7(15):1803-1812. |
| 90. | Sterman, D. H. et al. (May 1998). "Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase 1 Clinical Trial in Malignant Mesothelioma," <i>Hum. Gene Ther.</i> 9(7):1083-1092. |
| 91. | Stribling, R. et al. (December 1992). "Aerosol Gene Delivery In Vivo," <i>Proc. Natl. Acad. Sci. U S A</i> 89:11277-11281. |
| 92. | Sutton, M. A. et al. (1997). "Adenovirus-Mediated Suicide Gene Therapy For Experimental Bladder Cancer," <i>J. Urol.</i> 49(2):173-180. |
| 93. | Szejtli, J. (1994). "Medicinal Applications of Cyclodextrins," <i>Med. Res. Rev.</i> 14(3):353-386. |
| 94. | Taniguchi, K. et al. (1999). "Systemic Immune Response After Intravesical Instillation of Bacille Calmette-Guérin (BCG) for Superficial Bladder Cancer," <i>Clin. Exp. Immunol.</i> 115:131-135. |
| ** 95. | Tenjarla, S. et al. (April 1998). "Preparation, Characterization, and Evaluation of Miconazole-Cyclodextrin Complexes for Improved Oral and Topical Delivery," <i>J. Pharm. Sci.</i> 87(4):425-429. |
| 96. | Templeton, N. S. et al. (July 1997). "Improved DNA: Liposome Complexes for Increased Systemic Delivery and Gene Expression," <i>Nature Biotech.</i> 15(7):647-652. |
| 97. | Toda, M. et al. (May 1998). "In Situ Cancer Vaccination: An IL-12 Defective Vector /Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity," <i>J. of Immun.</i> 160(9):4457-4464. |
| 98. | Torre-Amione, G. et al. (February 1990). "A Highly Immunogenic Tumor Transfected with a Murine Transforming Growth Factor Type β_1 cDNA Escapes Immune Surveillance," <i>Proc. Natl. Acad. Sci. U S A</i> 87:1486-1490. |
| 99. | Vigneron, J-P. et al. (September 1996). "Guanidinium-Cholesterol Cationic Lipids: Efficient Vectors for the Transfection of Eukaryotic Cells," <i>Proc. Natl. Acad. Sci. U S A</i> 93:9682-9686. |
| 100. | von der Leyen, H. E. et al. (February 1995). "Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene," <i>Proc. Natl. Acad. Sci. U S A</i> 92:1137-1141. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 488002000200

Application Number 10/086,973

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Kesavan ESUVARANATHAN, et al.

Filing Date March 1, 2002

Group Art Unit 1645

Mailing Date: October 3, 2002

- | | |
|------|---|
| 101. | Weiss, D. J. et al. (September 1997). "In Situ Histochemical Detection of β -Galactosidase Activity in Lung: Assessment of X-Gal Reagent in Distinguishing <i>lacZ</i> Gene Expression and Endogenous β -Galactosidase Activity," <i>Hum. Gene Ther.</i> 8:1545-1554. |
| 102. | Werthman, P. E. et al. (February 1996). "Adenoviral-P53 Gene Transfer to Orthotopic and Peritoneal Murine Bladder Cancer," <i>J. Urol.</i> 155:753-756. |
| 103. | Whartenby, K. A. et al. (April 1995). "Gene-Modified Cells for the Treatment of Cancer," <i>Pharm. Ther.</i> 66(1):175-190. |
| 104. | Wheeler, C. J. et al. (October 1996). "A Novel Cationic Lipid Greatly Enhances Plasmid DNA Delivery and Expression in Mouse Lung," <i>Proc. Natl. Acad. Sci. U S A</i> 93(21):11454-11459. |
| 105. | Zabner, J. et al. (August 1995). "Cellular and Molecular Barriers to Gene Transfer by A Cationic Lipid," <i>J. Biol. Chem.</i> 270(32):18997-19007. |
| 106. | Zhang, Y. et al. (1997). "Effects of Bacillus Calmette-Guérin and Interferon- α -2B on Human Bladder Cancer <i>In Vitro</i> ," <i>Int. J. Cancer</i> 71:851-857. |
| 107. | Zhao, Q. et al. (1995). "Use of Cyclodextrin and its Derivatives as Carriers for Oligonucleotide Delivery," <i>Anti. Res. and Devel.</i> 5:185-192. |
| 108. | Zhu, N. et al. (July 1993). "Systemic Gene Expression After Intravenous DNA Delivery into Adult Mice," <i>Science</i> 261(5118):209-211. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.